Evidence map›Paper›PMID 27011358›Full record

ArticleBiofabrication2016

Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip.

Sejoong Kim, Sasha Cai LesherPerez, Byoung Choul C Kim, Cameron Yamanishi, Joseph M Labuz, Brendan Leung, Shuichi Takayama

Open access · greenAbstract read
In one paragraph

Article in Biofabrication, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. A Cell Pre-Wrapping Seeding Technique for Hydrogel-Based Tubular Organ-On-A-Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Organ Chips and Visualization of Biological Systems.Advances in experimental medicine and biology · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sejoong KimDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-7238-9962
Sasha Cai LesherPerezDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Byoung Choul C KimDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Cameron YamanishiDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Joseph M LabuzDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Brendan LeungDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Shuichi TakayamaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · USSeoul National University · KR

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Microfluidics in Biomedical Sciences Training ProgramT32EB005582 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, XUDONG · 2005 to 2020
$3.9M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Microfluidic Analysis of Oscillatory Signaling Pathways Using Phase LockingR01GM096040 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAKAYAMA, SHUICHI · 2011 to 2014
$1.1M
NHLBI NIH HHS NIH T32 HL007749NHLBI NIH HHS T32 HL007749NIBIB NIH HHS NIH T32 EB005582NIBIB NIH HHS T32 EB005582NIDCR NIH HHS T32 DE007057NIGMS NIH HHS GM096040NIGMS NIH HHS R01 GM096040NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Nephrotoxicity is often underestimated because renal clearance in animals is higher compared to in humans. This paper aims to illustrate the potential to fill in such pharmacokinetic gaps between animals and humans using a microfluidic kidney model. As an initial demonstration, we compare nephrotoxicity of a drug, administered at the same total dosage, but using different pharmacokinetic regimens. Kidney epithelial cell, cultured under physiological shear stress conditions, are exposed to gentamicin using regimens that mimic the pharmacokinetics of bolus injection or continuous infusion in humans. The perfusion culture utilized is important both for controlling drug exposure and for providing cells with physiological shear stress (1.0 dyn cm(-2)). Compared to static cultures, perfusion culture improves epithelial barrier function. We tested two drug treatment regimens that give the same gentamycin dose over a 24 h period. In one regimen, we mimicked drug clearance profiles for human bolus injection by starting cell exposure at 19.2 mM of gentamicin and reducing the dosage level by half every 2 h over a 24 h period. In the other regimen, we continuously infused gentamicin (3 mM for 24 h). Although junctional protein immunoreactivity was decreased with both regimens, ZO-1 and occludin fluorescence decreased less with the bolus injection mimicking regimen. The bolus injection mimicking regimen also led to less cytotoxicity and allowed the epithelium to maintain low permeability, while continuous infusion led to an increase in cytotoxicity and permeability. These data show that gentamicin disrupts cell-cell junctions, increases membrane permeability, and decreases cell viability particularly with prolonged low-level exposure. Importantly a bolus injection mimicking regimen alleviates much of the nephrotoxicity compared to the continuous infused regimen. In addition to potential relevance to clinical gentamicin administration regimens, the results are important in demonstrating the general potential of using microfluidic cell culture models for pharmacokinetics and toxicity studies.

Indexed as

Kidneys, ArtificialLab-On-A-Chip DevicesAnimalsAnti-Bacterial AgentsDogsDose-Response Relationship, DrugEquipment DesignEquipment Failure AnalysisGentamicinsKidneyMadin Darby Canine Kidney CellsMetabolic Clearance RateToxicity TestsAnti-Bacterial AgentsGentamicins

Identifiers

PMID27011358
PMCPMC12277022
OpenAlexW2308070823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.